Primary Total: $52,502,661
Total: $42,538,086
Primary Total: $39,077,134
Total: $2,889,199
Primary Total: $704,195
*Treatment of Behavioral Agitation in Alzheimer's Disease, (428327), Univ of California San Diego, $28,438 (adjustment).
*A Multicenter, Open-Label, Study of the Safety and Tolerability of Metrifonate (BAY A 9826) in Patients with Probable Alzheimer's Disease, (428749), Miles Laboratories Inc, $57,427 (adjustment).
*A Multi-center, Open-Label Study of the Safety and Tolerability of Metrifonate (Bay A 9826) in Patients with Probable Alzheimer's Disease, (429754), Bayer Pharmaceuticals, $7,500.
Cotinine Levels in Chronic Schizophrenic Inpatients, (429691), Natl Alliance for Research on Schizophrenia and, $15,000 (adjustment).
Physician Scientist Research Career Development Award, (427413), American Academy of Child & Adolescent Psychiatry, $86,823 (adjustment).
*Drug Abuse Prevention -- A Lifecourse Perspective Phase III, (433327), Natl Institute on Drug Abuse, $213,083.
Psychiatry Research and Program Development, (424942), KY Cab for Human Resources, $100,000 (adjustment).
*KRCC Evaluation, (429355), KY River Community Care Inc, $51,036 (adjustment).
*Drug Abuse Prevention -- A Lifecourse Perspective Phase III, (433326), Natl Institute on Drug Abuse, $179,962.
*State Demands and Needs Assessment, (433271), KY Cab for Human Resources, $290,370.
*Followup/Data Systems Treatment, (433272), KY Cab for Human Resources, $258,100.
*Aids Prevention for Drug Injectors in KY, (429850), Natl Institute on Drug Abuse, $424,413.
*Institute on Women and Substance Abuse, (433273), KY Cab for Human Resources, $207,300.
*Combination of Three Programs State Demands and Needs Assessment Followup/Data Systems Treatment Institute on Women and Substance Abuse, (429160), KY Cab for Human Resources, $54,070.
*Developing a Rural Behavioral Therapy Stage I, (429883), Natl Institute on Drug Abuse, $159,460.
*A Double-Blind Comparison of Sertindole and Haldol: An Assessment of the Chronic Safety, Efficacy,
Quality of Life and Relapse in Stable Schizophrenic Patients, (428031), Abbott Laboratories, $37,143 (adjustment).
*A Randomized Trial to Assess the Outcomes and Costs of Risperdal versus Conventional Antipsychotic Therapy in Patients with Chronic Schizophrenia, (429319), Janssen Research Fdtn, $1,000 (adjustment).
*Dose Response Study in the Treatment of Negative symptoms of Schizophrenia with Pramipexole, (429315), Upjohn Company, $11,480.
*Cynthia Hartung: Understanding Disinhibition in ADHD and CD Adolescents, (429358), Natl Institute of Mental Health, $26,920.
*Model State Supported AHEC Programs, (429652), Univ of Louisville, $141,000.
*Kentucky Health Education and Training Center, (429681), Univ of Louisville, $194,400.
*Developing Telemedicine Capacity in Eastern Kentucky, (429528), Health Resources and Services Administration, $482,988.
*Evaluation of Personality Functioning Following Traumatic Head Injury Using the NEO-PI-R, (429660), Kentucky Spinal Cord and Head Injury Trust, $29,351.
Private Child Care - Level of Care, (429412), KY Department for Social Services, $473,021.
*A Multicenter, Double-Blind, Placebo-Controlled Trial to Evaluate the Safety and Efficacy of Metrifonate (BAY A 9826) in Patients with Probable Alzheimer's Disease D95-018, (429559), Bayer Pharmaceuticals, $114,684.
For questions regarding listings, contact Ms. Deborah Davis, director of the Office of Sponsored Projects Administration, 214 Kinkead Hall, 0057, phone 257-8311. (ddavis@pop.uky.edu )
Last Updated: 6/30/03